Retatrutide
Retatrutide is an investigational injectable peptide that activates GLP-1, GIP, and glucagon receptors to reduce appetite, slow gastric emptying, and boost energy expenditure. This triple action has produced substantial weight loss and improved glucose control in clinical trials.
Retatrutide
Half-Life
Approx 6 days
Route
Subcutaneous
Typical Dose
4–12 mg once weekly
Mechanism / Target
GLP-1, GIP, and glucagon receptors
Evidence Level
Human phase 2–3 RCTs
Primary Research Use
Obesity and type 2 diabetes research
Mechanism: Activates GLP-1, GIP, and glucagon receptors to suppress appetite, increase insulin secretion, and promote fat oxidation and energy expenditure.
This information is for research only. Not intended for human use.
Overview
Retatrutide is a once-weekly injectable peptide that targets three receptors—GLP-1, GIP, and glucagon—making it a triple agonist. It is being studied for obesity, type 2 diabetes, and related metabolic conditions like fatty liver disease (MASLD) and chronic kidney disease.
In phase 3 trials, retatrutide reduced HbA1c by up to 1.94% and body weight by 15.3% over 40 weeks in people with type 2 diabetes, with gastrointestinal side effects that were generally manageable. In obesity without diabetes, weight loss reached 24.2% at 48 weeks. It also significantly lowered liver fat in MASLD, with 86% of participants on the highest dose achieving normal liver fat at 24 weeks.
Retatrutide remains investigational and is not approved by the FDA, but it is being evaluated in large phase 3 programs for obesity and its complications.
How it works
Retatrutide works by activating three different hormones at once: GLP-1, GIP, and glucagon. This triple action creates a stronger metabolic effect than targeting any single hormone alone.
How each receptor contributes
- GLP-1: Suppresses appetite, slows stomach emptying, and boosts insulin release when blood sugar is high. This reduces calorie intake without dangerously dropping blood sugar.
- GIP: Enhances the body’s insulin response and may improve how fat cells handle nutrients, which helps with insulin sensitivity.
- Glucagon: Increases fat burning in the liver and raises overall energy expenditure, counteracting the slowdown in metabolism that often comes with weight loss.
Secondary effects
Retatrutide also appears to remodel fat tissue to reduce inflammation and fibrosis, lower blood pressure, improve kidney markers, and reduce liver fat through changes in lipid metabolism. In humans, it raises compounds linked to fat burning (like 3-hydroxybutyrate) and lowers proteins that raise cholesterol.
Duration of action
With a half-life of about 6 days, retatrutide is dosed just once a week subcutaneously.
Documented effects
Weight loss
Retatrutide produces larger weight loss than most obesity treatments. In a phase 2 trial, people with obesity lost up to 24.2% of their starting weight after 48 weeks on the highest dose. In diabetes, weight loss reached 15.3% at 40 weeks.
Blood sugar control
HbA1c, a measure of long-term blood sugar, fell by 1.69% to 1.94% from baseline in type 2 diabetes trials, with placebo-adjusted reductions of 0.88% to 1.12%. The effect is dose-dependent and accompanied by improved insulin sensitivity markers like HOMA-IR and adiponectin.
Liver fat
In a dedicated MASLD study, liver fat decreased by 42.9% to 82.4% depending on dose, with most participants on 8–12 mg normalizing liver fat to below 5%.
Appetite and eating behavior
Higher doses reduced hunger, disinhibition, and prospective food consumption, and increased dietary restraint.
Metabolic and kidney signals
Retatrutide lowered triglycerides, LDL-related markers, and blood pressure. It also reduced albuminuria (a kidney damage marker), although effects on kidney filtration rate are still being studied.
Research protocols
All clinical trial protocols used retatrutide as a once-weekly subcutaneous injection, with slow dose escalation to improve gastrointestinal tolerance. Starting doses typically ranged from 0.5–2 mg, increasing every four weeks to a maintenance dose of 4–12 mg depending on the condition studied.
For obesity research, a common community approach mimics the trial design:
- Starting dose: 1–2 mg weekly for 4 weeks.
- Step-ups: Increase by 1–2 mg every 4 weeks as tolerated.
- Maintenance: 8–12 mg weekly for maximal weight loss.
GI side effects are the main reason for slower titration. Research protocols often held dose increases if significant nausea, vomiting, or diarrhea occurred.
Duration
Trials lasted 36–48 weeks, with weight loss not plateauing by the end. Chronic use is the expected model, as stopping GLP-1-based therapies typically leads to weight regain.
Starting dose
Assess GI tolerability.
Titration to 2 mg
Titration to 4 mg
Titration to 8 mg
Maintenance
This information is for research only. Not intended for human use.
Reconstitution and storage
Retatrutide used in clinical trials came as a ready-to-inject solution, so exact home reconstitution guidance comes from general peptide handling practices rather than the trials themselves.
When research-grade lyophilized retatrutide is used, bacteriostatic water is typically the diluent for multi-dose vials. The peptide is delicate: swirl gently to dissolve, never shake. Avoid repeated freezing and thawing.
Storage
- Unmixed powder: Store in the refrigerator (2–8°C) or frozen (-20°C) for longer term.
- After mixing: Keep refrigerated and use within 28–45 days if bacteriostatic water was used, or within 7–14 days if sterile water was used. Discard if the solution becomes cloudy or contains particles.
An interactive reconstitution calculator is available on this page to help determine the right volume for any dose and vial size.
Concentration
25 mcg / unit
Draw Volume
160 units (1.6 ml)
Doses Per Vial
1 doses
Total Solution
200 units (2 ml)
This information is for research only. Not intended for human use.
Interactions
Retatrutide’s main interactions come from its effects on gastric emptying, appetite, weight, and blood pressure rather than drug-metabolizing enzymes.
Medications that may need adjustment
- Insulin and sulfonylureas: These can cause low blood sugar when appetite and glucose levels drop. Doses often need to be reduced when starting retatrutide.
- Blood pressure drugs: Weight loss and the drug itself lower blood pressure; antihypertensives may need downward titration to avoid dizziness.
- Diuretics and SGLT2 inhibitors: Combined with reduced fluid intake or GI losses, these raise the risk of dehydration and kidney stress.
- Oral contraceptives: Vomiting or delayed gastric emptying could reduce absorption; backup contraception is advised during titration.
- Warfarin and other narrow-index oral drugs: Absorption may become inconsistent with delayed gastric emptying and GI symptoms, requiring closer monitoring.
Peri-anesthesia risk
Because retatrutide slows stomach emptying, standard fasting may leave residual stomach contents, increasing aspiration risk during sedation or surgery. Anesthesia teams should be informed of recent dosing.
Supplements
- Avoid high-dose magnesium or laxatives during GI-sensitive periods.
- Stimulant fat burners can add to heart rate increases.
- Berberine may compound glucose lowering.
Stacking
Retatrutide should not be combined with other GLP-1, GIP, or glucagon agonists because the overlapping mechanisms dramatically increase GI side effects without evidence of added benefit. This includes semaglutide, tirzepatide, liraglutide, and other incretin mimics.
Potentially synergistic combinations (research only)
- Amylin analogs (e.g., cagrilintide): Could amplify appetite suppression, but nausea and slowed gastric emptying would likely worsen. Only under specialist supervision.
- Growth hormone secretagogues: No direct receptor conflict, but the appetite reduction from retatrutide may make it difficult to eat enough to support anabolic goals.
If switching from another weekly incretin, the typical advice is to allow a full week after the last dose of the previous drug before starting retatrutide at the lowest dose, rather than trying to match equivalent doses.
Regulatory status
In the United States, retatrutide is investigational and not FDA-approved for any condition, though it has completed a phase 3 diabetes trial and is in phase 3 for obesity (the TRIUMPH program). It is not scheduled by the DEA and has no established abuse-liability classification.
Internationally, retatrutide is not yet approved by the EMA, MHRA, or TGA. Ongoing multinational trials include sites in Europe and North America.
Sports and anti-doping
Retatrutide’s status under WADA is not explicitly stated in the available research, but as an unapproved metabolic peptide, athletes should consider it high risk until verified. Use of gray-market investigational peptides adds contamination and legitimacy concerns.
Compounding of retatrutide sits in a legally gray area, and commercial availability outside clinical trials is not supported by the drug’s developers.
Safety and side effects
The most common side effects of retatrutide in clinical trials are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are dose-related and tend to ease over time, but can be severe enough to require stopping the drug. In a phase 3 diabetes study, 2–5% discontinued because of adverse events.
Other known effects
- Heart rate: A modest increase in resting heart rate is typical for GLP-1-based therapies and has been observed with retatrutide.
- Blood pressure: Usually goes down, which can cause dizziness in some people, especially if they are also taking blood pressure drugs.
- Kidney markers: Changes in kidney filtration rate (eGFR) have been seen, but whether this reflects benefit or harm is still under study.
- Gallbladder and pancreas: Like other incretin therapies, there is a theoretical risk of gallbladder problems and pancreatitis, though specific rates are not yet established.
Rare concerns
- One case report described intractable diarrhea.
- A safety signal for unusual skin sensations (dysesthesia) has been noted across the GLP-1 class and may apply to retatrutide.
When to be cautious
Retatrutide should be avoided or used with extreme care in people with severe stomach-emptying disorders, active vomiting, unstable heart arrhythmias, advanced kidney disease with fluid shifts, or during anesthesia because of delayed stomach emptying. It is not recommended during pregnancy or breastfeeding due to lack of data.
Frequently asked questions
Is retatrutide FDA-approved?+
No. As of the corpus, retatrutide is still investigational, with completed phase 2 obesity and diabetes trials, an ongoing phase 3 obesity program (TRIUMPH), a completed phase 3 monotherapy diabetes trial, and ongoing kidney-outcomes/mechanistic studies. It is not described in the corpus as having current FDA approval for obesity, diabetes, or MASLD/MASH.
How is retatrutide usually dosed?+
Human trial dosing is once-weekly subcutaneous injection with step-up titration rather than starting at the target dose (RCT). In obesity phase 2, studied maintenance doses were 1, 4, 8, and 12 mg weekly over 48 weeks; in diabetes phase 3, 4, 9, and 12 mg weekly were used over 40 weeks. GI intolerance was more common with higher doses and more aggressive escalation, so slow titration is the practical default.
Typical titration pattern (community protocol):
- 1–2 mg weekly start
- increase every 4 weeks if tolerated
- common maintenance: 4–8 mg weekly
- advanced users targeting maximal weight loss: 9–12 mg weekly This mirrors the trial logic of gradual escalation and GI management.
How much weight loss can people expect?+
Retatrutide is among the most potent obesity drugs studied so far (RCT). In the 48-week obesity phase 2 trial, the highest-dose arms reached about 24.2% mean body-weight reduction at 48 weeks. In phase 3 monotherapy for type 2 diabetes, mean weight change at 40 weeks was -11.5% with 4 mg, -13.9% with 9 mg, and -15.3% with 12 mg versus -2.6% with placebo. Weight loss is progressive over months, not days, and higher doses generally produce greater effect.
Does retatrutide lower blood sugar too?+
Yes, strongly (RCT). In phase 3 type 2 diabetes, HbA1c fell by -1.69% with 4 mg, -1.86% with 9 mg, and -1.94% with 12 mg at week 40 versus -0.81% with placebo. In the earlier phase 2 diabetes trial, HbA1c reductions reached about 2.0% with higher doses, with concurrent weight loss up to roughly 17% by week 36. This makes it useful for people with both obesity and dysglycemia, but it also means glucose-lowering co-medications may need adjustment (practitioner consensus).
What side effects are most common?+
Gastrointestinal effects dominate: nausea, vomiting, diarrhea, constipation, reduced appetite, and early satiety (RCT). These were generally mild to moderate and tended to subside over time, but discontinuation due to adverse events increased with dose and faster escalation; in phase 3 diabetes, discontinuation due to adverse events was 2–5% with retatrutide versus 0% with placebo. Retatrutide also delays gastric emptying, which likely contributes to fullness and GI effects.
Practical mitigation (practitioner consensus):
- escalate slowly
- avoid large/high-fat meals on injection day and the day after
- stop eating at first clear satiety signal
- prioritize fluids/electrolytes if diarrhea or vomiting occurs
Is retatrutide better than semaglutide or tirzepatide?+
For weight loss, retatrutide appears numerically stronger than current single- and dual-incretin comparators across separate trials, but there are limited direct head-to-head data (RCT + indirect evidence). Obesity phase 2 data showed retatrutide up to ~24.2% at 48 weeks, whereas large comparative reviews rank semaglutide and tirzepatide as top approved agents and note retatrutide as highly promising but still investigational. Mechanistically, retatrutide adds glucagon receptor agonism to GLP-1/GIP activity, which may contribute to higher energy expenditure and broader lipid effects.
Practical ranking (practitioner consensus):
- best-established approved option: tirzepatide
- best investigational weight-loss potency: retatrutide
- if tolerability is priority, tirzepatide/semaglutide may be easier starts
Does Retatrutide help liver fat, cholesterol, or blood pressure?+
Yes, early evidence is strong for metabolic remodeling (RCT). In MASLD phase 2a, liver fat fell by -42.9% to -82.4% at 24 weeks depending on dose, and 79–86% of participants on 8–12 mg normalized liver fat to <5% versus 0% on placebo. Retatrutide also improved lipid and metabolite profiles, including triglycerides, LDL-related markers, and fatty-acid-oxidation signatures. Blood pressure reductions were also reported in obesity and diabetes programs, though BP outcomes are secondary rather than primary efficacy targets.
Can people with kidney disease use retatrutide?+
Potentially, but evidence is still developing (mechanistic trial + post-hoc clinical data). A dedicated 24-week phase 2b CKD mechanistic trial is underway in adults with overweight/obesity and eGFR 25–75 mL/min/1.73 m², with or without type 2 diabetes, using weekly retatrutide up to 12 mg. Earlier post-hoc analyses suggested reduced albuminuria and blood pressure, with eGFR effects differing by diabetes status. For now, CKD is not a reason to assume benefit or harm automatically; use requires closer monitoring of hydration, GI tolerance, creatinine/eGFR, and albuminuria (practitioner consensus).
How long can I stay on retatrutide?+
Trials studied 36–48 weeks in phase 2 and 40 weeks in phase 3 diabetes, with longer phase 3 obesity programs ongoing (RCT). Obesity should be treated as a chronic disease; benefits are expected to persist only while therapy is maintained, as with the broader GLP-1 class, where stopping treatment is commonly followed by partial weight regain. In practice, long-term use is the expected model if efficacy and tolerability remain acceptable (practitioner consensus).
Can I use Retatrutide while pregnant, trying to conceive, or breastfeeding?+
Avoid it in those settings (class-based precaution; no robust retatrutide-specific human pregnancy dataset in the corpus). The corpus does not provide adequate pregnancy or lactation safety data for retatrutide, and its strong effects on weight, appetite, gastric emptying, and glucose regulation make exposure undesirable during pregnancy. Standard practice is to discontinue before conception attempts and avoid during breastfeeding (practitioner consensus).
Can I travel with retatrutide, and does Retatrutide need special handling?+
It is a once-weekly injectable, so travel is simpler than daily regimens (RCT context). Exact storage instructions are product-specific and not established in the corpus because retatrutide is investigational, but standard peptide-handling practice is to keep pens or vials protected from heat/light and use an insulated medication pouch during travel (practitioner consensus). Because GI symptoms can be worse after dosing, many users schedule injections so the first 24–48 hours do not overlap with flights, long drives, or major events (community protocol).
References
- 1.Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialBajaj, et al. · 2026
- 2.Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney diseaseHeerspink, et al. · 2025
- 3.Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialSanyal, et al. · 2024
- 4.Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesPearson, et al. · 2026
- 5.Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 studyKanu, et al. · 2025
- 6.Decreases in circulating <scp>ANGPTL3</scp> /8 concentrations following retatrutide treatment parallel reductions in serum lipidsWen, et al. · 2025
- 7.Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the <scp>TRIUMPH</scp> registrational clinical trialsGiblin, et al. · 2025
- 8.The novel <scp>GIP</scp> , <scp>GLP</scp> ‐1 and glucagon receptor agonist retatrutide delays gastric emptyingUrva, et al. · 2023
- 9.Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff, et al. · 2023
- 10.Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock, et al. · 2023
- 11.A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of RetatrutideMao, et al. · 2026
- 12.Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese <scp>MASH</scp> Mouse and Hamster ModelsBriand, et al. · 2026
- 13.Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repairLi, et al. · 2026
- 14.Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditionsNeff · 2025
- 15.RetatrutideRetatrutide · 2025
- 16.Inotropic effects of retatrutide in isolated human atrial preparationsNeumann, et al. · 2025
- 17.GIPR:GCGR co-agonism restores normal weight in obese rodentsPerez-Tilve, et al. · 2026
- 18.Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff, et al. · 2023
- 19.The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or ObesityHeerspink, et al. · 2025
- 20.Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionBudini, et al. · 2026
- 21.Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesiaKang, et al. · 2026
- 22.Retatrutide-Induced Intractable DiarrheaKomolafe · 2026
- 23.Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysisBasile, et al. · 2025
- 24.Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature reviewLaroche, et al. · 2026
- 25.GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical ImplicationsMoiz, et al. · 2025
- 26.Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trialsZhang, et al. · 2026
- 27.Retatrutide-A Game Changer in Obesity PharmacotherapyKatsi, et al. · 2025
- 28.Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock, et al. · 2023
- 29.Therapeutic peptides and proteins: Status and developments in drug deliveryHornsby, et al. · 2026
- 30.754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 TrialsHEERSPINK, et al. · 2024
- 31.GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple AgonistsAbid, et al. · 2026
- 32.Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future PerspectivesRenke, et al. · 2026
Last reviewed on Jun 22, 2026
Have more questions about Retatrutide?
Ask ChatPEP for protocols, stacking, and cited research tailored to your goals.